Staszewski S - Search Results

1

Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.

Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B. Smith CJ, et al. Among authors: staszewski s. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1155-9. doi: 10.1097/01.qai.0000135958.80919.e4. J Acquir Immune Defic Syndr. 2004. PMID: 15319675

2

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S. Geretti AM, et al. Among authors: staszewski s. Antivir Ther. 2008;13(7):927-36. Antivir Ther. 2008. PMID: 19043927

3

Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.

Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: staszewski s. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.

4

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN. Lampe FC, et al. Among authors: staszewski s. Arch Intern Med. 2006 Mar 13;166(5):521-8. doi: 10.1001/archinte.166.5.521. Arch Intern Med. 2006. PMID: 16534038

5

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte Ad, Rakhmanova A, Phillips AN, Lundgren JD; EuroSIDA study group. Mocroft A, et al. Among authors: staszewski s. Antivir Ther. 2007;12(3):325-33. Antivir Ther. 2007. PMID: 17591022 Clinical Trial.

6

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. Fox ZV, et al. Among authors: staszewski s. AIDS. 2007 Oct 1;21(15):2033-42. doi: 10.1097/QAD.0b013e32825a69e4. AIDS. 2007. PMID: 17885293 Clinical Trial.

7

Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?

Stephan C, Dauer B, Khaykin P, Stuermer M, Gute P, Klauke S, Staszewski S. Stephan C, et al. Among authors: staszewski s. Curr HIV Res. 2009 May;7(3):320-6. doi: 10.2174/157016209788348010. Curr HIV Res. 2009. PMID: 19442129

8

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.

Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration. Moore DM, et al. Among authors: staszewski s. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63. doi: 10.1097/QAI.0b013e3181b62933. J Acquir Immune Defic Syndr. 2009. PMID: 19668084 Free PMC article.

9

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: staszewski s. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821

10

Definition of loss of virological response in trials of antiretroviral drugs.

Staszewski S, Sabin C, Dauer B, Lepri AC, Phillips A. Staszewski S, et al. AIDS. 2003 Sep 5;17(13):1997-8. doi: 10.1097/00002030-200309050-00024. AIDS. 2003. PMID: 12960838

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters